Piper Alderman advises on international life sciences company merger


Piper Alderman has advised Brandwood CKC on its merger with international life sciences consultancy, PharmaLex Group.

Brandwood CKC is now part of the privately-owned PharmaLex Group, establishing an Australian presence for PharmaLex.

Brandwood CKC formed in 2019, following the merger of two leading Australian consulting firms, offers a range of regulatory, technical, and commercial services for developers, manufacturers and suppliers of medical devices, diagnostics and pharmaceutical products.

Piper Alderman Partner, Lis Boyce, and Associate, Bahar Agar, advised Sydney-based Brandwood CKC on the deal. They assisted the board and shareholders of Brandwood CKC with negotiating and implementing the transaction documents, as well as planning for post-completion operations. The corporate team was supported by Tim Capelin, advising on employment aspects of the deal and Samantha Gou, advising on leasing negotiations.

Commenting on the deal, Lis Boyce said:

“Having worked with Brandwood CKC for a number of years, including the 2019 merger, it is very gratifying to have supported the team through this next important stage of growth and exciting to see the strategic potential for both organisations in the combination with Pharmalex.”

Brandwood CKC managing director Grant Bennett said:

The merger allows us to expand the range and geographical reach of services we can provide our clients, as well as supporting PharmaLex by providing global expertise in the medical device and diagnostic sectors.

We have always provided solid experience-backed support to clients, including access into Europe and the USA.  However, having the support and access of PharmaLex in these regions, takes us to the next level.

The opportunity the merger provides to our clients and international markets is a huge value add, and the support provided by Piper Alterman was invaluable to ensuring the transaction ran seamlessly.”


Related media coverage